Sanofi's Sarclisa Escena Gets FDA Green Light for First On-Body Cancer Injector
Context mode is active. Hover over any highlighted term to see its definition. Click a nested term to go deeper.
Sanofi has just secured a landmark approval from the US Food and Drug Administration (FDA) for Sarclisa Escena SC, making it the first anticancer treatment that can be given through an innovative on-body injector (OBI) device. This is big news for patients battling multiple myeloma, offering a much more convenient way to receive their vital medication outside of a clinic. The approval of this subcutaneous (SC) formulation, delivered via the CirCLIQ on-body injector, is expected to significantly improve the treatment experience by reducing clinic visit times and the burden on healthcare staff. This move intensifies Sanofi competition with Johnson & Johnson's Darzalex Faspro, another key anti-CD38 monoclonal antibody treatment that already has a subcutaneous option. While Darzalex Faspro also offers convenience, Sarclisa Escena's new on-body injector sets a new standard for ease of use, as proven by the pivotal IRAKLIA Phase 3 study. This study showed that the OBI delivery offered similar efficacy and safety to the traditional intravenous (IV) method, but with much shorter administration times and fewer infusion-related reactions. Looking ahead, this approval could kickstart a wider adoption of on-body injector technology in oncology, potentially transforming how many cancer treatments are delivered. Sanofi will now roll out Sarclisa Escena SC across all approved indications for its IV version in multiple myeloma, which includes patients with newly diagnosed, and relapsed or refractory multiple myeloma. This development not only benefits patients with greater flexibility and comfort but also eases the workload on nurses and healthcare systems, paving the way for more home-based cancer care.